Kidney diseases are highly prevalent worldwide, and significantly reduce the quality of life of patients, creating an urgent need for effective therapeutic modalities. Despite this significant unmet medical need, none of the drugs launched to date have demonstrated promising potential to cure kidney diseases. This is likely due to the structural complexity of the kidney as well as difficulties in setting appropriate endpoints for clinical trials and identifying appropriate therapeutic targets. Recently, an alternative endpoint for clinical trials (i.e., a 30% or 40% reduction in estimated glomerular filtration rate [eGFR] from baseline following 2-3 years of observation) has been considered in the United States, European Union, and Japan, and is expected to contribute to the progress of drug development for kidney diseases. Further, oxidative stress and inflammation are currently thought to be key factors in the progression of kidney diseases, prompting more research on drugs targeting the mechanisms related to these factors for treatment. The Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) system has drawn much attention in recent years for its anti-oxidative and anti-inflammatory properties, and its pharmacological potential for treatment of kidney diseases is being widely investigated in both clinical and non-clinical studies. This review summarizes the current issues in the treatment of kidney diseases, including clinical endpoints, Nrf2 activators as treatment options, and perspectives on pharmaceutical applications of Nrf2 activators.
Introduction
Kidney diseases are highly prevalent worldwide, and significantly reduce the quality of life (QOL) of patients (Cruz et al. 2011) , creating an urgent need for effective therapeutic modalities. The two main types of kidney diseases, acute kidney injury (AKI) and chronic kidney disease (CKD), are defined in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. In recent years, however, AKI has been identified as a risk factor for CKD (Ishani et al. 2011; Palomba et al. 2017) , thus suggesting that the two diseases are closely associated with one another.
Patients with end-stage renal disease (ESRD), the last stage of CKD, require dialysis or a kidney transplant, which can further reduce the QOL and increase the burden of medical costs on patients. According to the United States Renal Data System (USRDS), the Medicare cost of CKD and ESRD in the United States (US) was estimated to be US$98 billion, accounting for about 18% of the total Medicare cost in the US. In Japan, medical cost related to renal disorders was estimated to be 1.6 trillion yen (US$14 billion), indicating that kidney diseases have a significant impact on healthcare economics. However, despite such significant unmet medical need, none of the drugs launched to date have demonstrated promising potential to cure kidney diseases.
Currently, the main therapeutic approach for CKD is to control the blood pressure using renin-angiotensin system inhibitors (angiotensinconverting enzyme inhibitors [ACEi] and angiotensin II receptor blockers [ARBs] ) (Holtkamp et al. 2011) . In addition, the beneficial effect of sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin on renal outcomes has also been shown (Wanner et al. 2016) . Although these drugs could be one of the treatment options for CKD, they are still suboptimal approaches and the need to develop new drugs for kidney diseases remains high.
This review aims to provide the future prospects of development of new drugs for kidney diseases from current issues including recent advancement of new clinical endpoints Matsushita T et al. 2016 ) and researches of the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) system, a key regulator of anti-oxidative and anti-inflammatory response (Yamamoto et al. 2018 ).
Advancement of new clinical endpoints for kidney diseases
One of the important characteristics desired in drugs for kidney diseases is the ability to maintain the glomerular filtration rate (GFR), which is an indicator of kidney function. Estimated GFR (eGFR), based on the serum creatinine level, is widely used to assess renal function. CKD patients are classified as stage G1-G5 based on their eGFR values, with the higher stages leading to increased risk for dialysis and kidney transplantation.
It is critical for clinical trials to have an appropriate design and endpoint. The traditional clinical endpoint of kidney diseases (especially CKD) has been the initiation of dialysis or a kidney transplant. However, the time needed to reach this stage is relatively long, making its use impractical in clinical trials. The doubling of serum creatinine (53%-57% reduction in eGFR) is used as an alternative endpoint; however, this index still requires long-term observation of many patients, and can contribute to the difficulty in developing drugs for kidney diseases. In recent years, there has been a shift toward identifying a new alternative endpoint for kidney diseases, i.e., a 30% or 40% reduction in eGFR from baseline following 2-3 years of observation, which has been discussed in the US, European Union (EU), and Japan Greene et al. 2014; Inker et al. 2014; Lambers Heerspink et al. 2014; Levey et al. 2014; Matsushita et al. 2016) . Worldwide, Japan ranks first in establishing guidelines using this endpoint (Kanda et al. 2018) , which can facilitate future drug development.
Antioxidants as a potential therapy for kidney diseases
As mentioned above, none of the drugs developed to date for kidney diseases have demonstrated potential to cure either AKI or CKD. One of the reason could be the complexity of the kidney as an organ system that comprises structures with different functions (including the glomeruli, renal tubules, and afferent and efferent arterioles), with numerous types of cells involved in the formation of these structures. In addition, the close association of systemic factors such as the cardiorenal continuum and vascular/circulatory abnormalities with renal function further complicate the disease treatment process (Clausen et al. 2001; Yilmaz et al. 2006; Liu et al. 2014a) , and appropriate therapeutic targets have yet to be identified.
Though the detailed mechanisms of CKD progression are not fully understood, the transition to ESRD has been suggested to occur via a final common pathway, and oxidative stress and inflammation are thought to be important factors in this pathway (Nangaku 2006; Mimura and Nangaku 2010; Yamaguchi et al. 2015) . Recent studies have demonstrated that mitochondrial dysfunction, with its consequent reduction in adenosine triphosphate (ATP) production, and renal fibrosis are also related to CKD progression, prompting further research targeting these mechanisms for treatment of kidney diseases (Gamboa et al. 2016; Galvan et al. 2017; Lv et al. 2018a,b) .
Several clinical trials conducted to date in the US and Europe have been designed to explore the effects of antioxidants such as vitamin E, N-acetyl cysteine and coenzyme Q10 to treat kidney diseases (Klein et al. 1995; Boaz et al. 2000; Singh et al. 2000; Tepel et al. 2003; Giannini et al. 2007; Parham et al. 2008; Grebe et al. 2013) . However, these studies were small-scale clinical trials and the efficacy of the investigated agents is currently inconclusive. AST-120, an orally administered spherical carbon adsorbent that can adsorb various small molecule uremic toxins and is reported to reduce oxidative stress (Nakagawa et al. 2006; Shimoishi et al. 2007 ), was evaluated in CKD patients in two randomized placebo-controlled global trials (Akizawa et al. 2009; Schulman et al. 2015) . Unfortunately, these trials were not able to demonstrate a beneficial effect of AST-120 on progression of CKD, defined as a composite of dialysis initiation, kidney transplantation, and serum creatinine doubling as a primary endpoint. In China, Tripterygium wilfordii Hook F, which is believed to have anti-inflammatory and anti-oxidative effects, has long been used for the treatment of CKD. Results of a meta-analysis also suggest that this agent has renal-protective effects (Zhu et al. 2013) . However, it is still insufficient for blocking the transition of CKD to ESRD, making it debatable whether antioxidant treatments can actually lead to an overall improvement in kidney diseases. Despite the multitude of studies showing an association between antioxidants and CKD progression, clear therapeutic effects of antioxidants on kidney diseases are yet to be demonstrated. As highlighted by Chen et al. (Chen and Siriki 2015) , the underlying problem might be that the effects of antioxidants examined to date are insufficient, perhaps because they provide a limited and finite anti-oxidative potential. It is conceivable that the development of new drugs with more potent anti-oxidative effects can significantly advance the treatment of kidney diseases.
Against this background, the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) system has drawn much attention in recent years for its anti-oxidative and antiinflammatory properties.
Keap1-Nrf2 system
The Keap1-Nrf2 system is activated by stimuli such as electrophilic compounds, reactive oxygen species (ROS), and endoplasmic reticulum stress, and controls cellular defense mechanisms against oxidative stress. A key protein in this system is the transcription factor Nrf2. Nrf2 function is negatively regulated by Keap1, which promotes its degradation via the ubiquitin-proteasome system under normal physiological conditions. When the cell is exposed to stimuli such as those mentioned above, Keap1 undergoes a conformational change, which in turn changes its association with Nrf2. Consequently, Nrf2 is released from the proteasome pathway and translocated to the nucleus. Upon translocation to the nucleus, Nrf2 forms a heterodimer with small musculoaponeurotic fibrosarcoma (sMAF) proteins, and activates the transcription of multiple downstream antioxidant gene clusters by binding the gene regulator antioxidant responsive element (Yamamoto et al. 2018) (Fig. 1 ).
Keap1-Nrf2 system and kidney diseases
A number of reports have described the association between Nrf2 and kidney diseases. Additionally, a review by Nezu et (Nezu et al. 2017) . The Nrf2-KO mutation results in the worsening of lupus-like nephritis, streptozotocin-induced renal disease (including renal function), ferric nitrilotriacetate-induced nephrotoxicity, and ischemia-reperfusion (IRI)-induced kidney injury. In contrast, the Keap1-KD mutation is associated with reduced IRI-induced tubular injury and reduced unilateral ureteral obstruction-induced renal fibrosis.
A number of studies have evaluated the effects of Nrf2 activators on kidney injury. Table 1 summarizes the recent findings for representative compounds (sulforaphane, curcumin, and synthetic triterpenoids (CDDO) such as bardoxolone methyl [CDDO-Me]) in rodent kidney disease models. Similar to the results in genetically modified animals, several other studies have also shown that Nrf2 activation leads to reduced kidney injury, indicating the therapeutic potential of targeting this pathway for treatment of kidney diseases.
Challenge in clinical application of the Nrf2 activators

Clinical trials of bardoxolone methyl for kidney disease
History -BEAM and BEACON studies
Although bardoxolone methyl was originally investigated as a chemotherapeutic agent (Hong et al. 2012 ), a marked increase in eGFR observed (26.4 ± 3.2% increase from baseline [mean baseline: 74.4 ± 3.5 mL/min/1.73 m 2 ]) in cancer patients led to the evaluation of bardoxolone methyl for treatment of kidney diseases. In a phase 2 trial (BEAM study), 227 patients with diabetic kidney disease (DKD) (stage G3-G4 CKD) were enrolled in a 52-week study. Marked increases in eGFR were observed across all dosage groups (25 mg (Pergola et al. 2011 ). However, a subsequent phase 3 trial (BEACON study) was prematurely terminated after enrolling 2185 DKD patients (stage G4 CKD) due to the increased rate of cardiovascular events (de Zeeuw et al. 2013) . Futher development of bardoxolone methyl for kidney diseases was therefore put on hold. A post-hoc analysis, however, found that the events of heart failure observed in BEACON study were associated with fluid overload that occurred early in the administration (at 3-4 weeks) (Chin et al. 2014a; Chin et al. 2014b ). In addition, a high basal brain natriuretic peptide (BNP) level (> 200 pg/mL) and history of hospitalization for heart failure were found to be risk factors (Chin et al. 2014a,b) . Futhermore, an additional post-hoc analysis suggested that Fig. 1 . Schematic image showing activation of the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) pathway. Nrf2 is released from the proteasome pathway and translocated to the nucleus as a result of conformational changes induced in Keap1 by stimuli such as reactive oxygen species (ROS) and electrophiles (e.g. CDDOs like bardoxolone methyl). Keap1 has 27 and 25 cysteine residues in humans and mice, respectively (Dinkova-Kostova et al. 2002; Zhang and Hannink 2003) . Three highly reactive cysteine residues (Cys151, Cys273, and Cys288) in Keap1 are well established as being essential for regulating Nrf2 function. CDDO is reported to be a Cys151-preffering inducer (Yamamoto et al. 2018) . Upon translocation to the nucleus, Nrf2 forms a heterodimer with small musculoaponeurotic fibrosarcoma (sMAF) proteins and activates the transcription of downstream antioxidant gene clusters by binding to the antioxidant responsive element.
Table 1
Rodent experiments of Nrf2 activators in kidney disease models. Oey et al. (2018) apoE, apolipoprotein E; αSMA, alpha smooth muscle actin; AKI, acute kidney injury; BUN, blood urea nitrogen; Ccr, creatinine clearance; CsA, Cyclosporine A; dh TFEA, dihydro trifluoethyl amide; EA, ethyl amide; Im, imidazole; Me, methyl; CIN, contrast-induced nephropathy; CKD, chronic kidney disease; DN, diabetic nephropathy; FeNTA, iron nitrilotriacetate; IRI, ischemia-reperfusion injury; Nrf2, nuclear factor erythroid 2-related factor 2; PKD, polycystic kidney disease; STZ, streptozotocin; UUO, unilateral ureteric obstruction; UACR, urinary albumin creatinine ratio; HFD, high fat diet. K. Yamawaki et al. Toxicology and Applied Pharmacology 360 (2018) 30-37 bardoxolone methyl may delay the onset of ESRD in CKD patients (Chin et al. 2018 ). These analysis results have encouraged us to restart clinical development of bardoxolone methyl for kidney disease.
A post-hoc analysis of BEACON study also showed that drug exposure levels were not associated with heart failure, when administered at 20 mg of amorphous spray-dried dispersion (SDD) bardoxolone methyl formulation (Chin et al. 2014b) . Although the activity and safety of 20 mg of amorphous SDD bardoxolone methyl is considered to be similar to those at 75 mg of crystalline formulation (de Zeeuw et al. 2013) , heart failure was not observed in stage G3 DKD patients dosed at 25-150 mg of crystalline per day in BEAM study. In addition, decreased sodium excretion and urine output occurred in some patients with stage 4 CKD but not those with stage 3b CKD in a separate study (Chin et al. 2014a) . Importantly, there was also no safety concerns after supratherapeutic dose (80 mg of amorphous SDD) in healthy volunteers (Chin et al. 2014a; Teuscher et al. 2014) . Taken together, these findings suggest that the occurrence of heart failure seen in BEACON study may have been associated with not dosage but certain target population, although it should be noted that patients have started with a low dose and titrated the dose slowly as a precaution in subsequent studies.
Revival -TSUBAKI, CARDINAL, PHOENIX and AYAME studies
Based on the detailed analysis of the BEACON study data, another phase 2 trial (TSUBAKI study) was initiated in Japan in 2015 in patients with DKD (stage G3-G4 CKD) with type 2 diabetes mellitus, excluding those with the risk factors mentioned above. Patients were monitored closely (e.g., body weight and blood pressure) for potential body fluid retention. Treatment was administered to 120 patients (placebo group, n = 41 [G3a/b] and n = 14 [G4]; bardoxolone methyl group, n = 41 [G3a/b] and n = 24 [G4]) at 5-15 mg of amorphous SDD per day for 16 weeks. Unlike the BEACON study, no cardiovascular events were observed, indicating that the risk of fluid retention could be averted by appropriate patient selection and monitoring. It should be noted that the efficacy of bardoxolone methyl was evaluated by the inulin clearance method, which is the gold standard for measuring GFR, to make a precise assessment of kidney function. Given that eGFR is derived from creatinine levels, the possibility could have existed that the observed elevation in eGFR was only an apparent change due to the impact of bardoxolone methyl on creatinine metabolism. The TSUBAKI study was designed to directly address this concern, and found that the change in GFR measured by inulin clearance from baseline after 16 weeks of administration was −0.69 mL/min/1.73 m 2 in the placebo group and + 5.95 mL/min/1.73 m 2 in the bardoxolone methyl group (Nangaku et al. 2017) , thereby showing that treatment with bardoxolone methyl leads to an improvement in kidney function, which was not associated with creatinine metabolism. In addition, no patients with stage G3 or G4 CKD in the study showed signs of body fluid retention that could pose a major safety concern, including heart failure. These results were well received and prompted the Japanese Ministry of Health, Labour and Welfare to grant priority review and designation system (SAKIGAKE designation) to bardoxolone methyl for treatment of DKD. This designation will allow closer cooperation with the authorities involved in the regulatory approval process, and the review period required for approval will be shortened. Moreover, a phase 3 trial of bardoxolone methyl (5-15 mg of amorphous SDD per day) in DKD (AYAME study, stage G3-G4 CKD), has been started in Japan in 2018, with 30% reduction in eGFR or ESRD used as a primary endpoint. In conjunction with primary completion of the TSUBAKI study, clinical trials of bardoxolone methyl for kidney diseases were resumed in the US in 2017 and are currently ongoing. Promising preliminary results were obtained in 30 CKD patients (stage G2-G3; mean baseline eGFR: 54 ± 24 mL/min/1.73 m 2 ) treated with bardoxolone methyl (5-30 mg of amorphous SDD per day) in the phase 2 portion of the phase 2/3 study for Alport syndrome (CARDINAL study), with a change in eGFR of +13.4 mL/min/1.73 m 2 observed at Week 12 (Block et al. 2017) and + 10.4 mL/min/1.73 m 2 observed at Week 48. Also, significant retained benefit at Week 52 after withdrawal of active drug for 4 weeks (by a mean of 4.1 mL/min/1.73 m 2 ) was observed (Reata Pharmaceuticals press release, 2018). Alport syndrome is a hereditary progressive nephritis caused by mutations in genes encoding the type IV collagens, which are major components of the glomerular basement membrane. Currently, there is no curative treatment for Alport syndrome despite its high lifetime risk for ESRD, and bardoxolone methyl is highly expected to be the first drug for this disease.
Furthermore, another phase 2 study, named PHOENIX study, is being conducted to explore its application to other rare CKD (stage G2-G3), e.g., autosomal dominant polycystic kidney disease (ADPKD), as shown in Table 2 . Recent data demonstrated that significant increase of eGFR (+9.3 mL/min/1.73 m 2 at Week 12) was observed in bardoxolone methyl treated ADPKD patients (5-30 mg of amorphous SDD per day (Reata Pharmaceuticals press release, 2018)). ADPKD is a genetic disorder characterized by the growth of numerous cysts in the kidneys, caused by mutations in the PKD1 and PKD2 gene and approximately 50% of individuals with ADPKD have ESRD by age 60 years (Harris et al., 2018) . Though tolvaptan has been the first approved drug for ADPKD, careful consideration for adverse events such as hepatotoxicity is needed for its use (Sans-Atxer and Joly 2018) and there is still no drug which improves the kidney function. Therefore, bardoxolone methyl could also bring hope to the ADPKD patients as a new therapeutic option.
Possible mechanism for improvement of kidney function
Two potential mechanisms by which bardoxolone methyl could improve kidney function include dynamic action on the glomerular filtration surface area and impact on chronic pathological inflammatory signaling and kidney structure (Fig. 2) . Of these, the dynamic action of bardoxolone methyl on GFR is likely due to the maintenance of intracellular redox homeostasis in mesangial cells and/or endothelial cells, resulting in a higher filtration coefficient (K f ). More specifically, the regulation of ROS-induced Ca ++ influx in mesangial cells, with consequent inhibition of mesangial cell contraction (Ding et al. 2013) , and preservation of endothelial cell function via improvement in nitric oxide bioavailability (Heiss et al. 2009; Aminzadeh et al. 2013) , could contribute to the improvement of kidney function. The AASK study on the L-type calcium blocker amlodipine is another example that a study drug caused an increase in GFR. However, amlodipine presumably caused an increase in glomerular pressure, which led to a transient increase in GFR followed by a decline of steeper slope (Wright et al., 2002; Delles et al. 2003) . Results from the AASK study may indicate that the mechanism of the increase in GFR produced by bardoxolone methyl is different from that of amlodipine. Bardoxolone methyl produces increases in GFR that are sustained for at least 1 year and partially retained even after 4 weeks of drug withdrawal, suggesting that the increase in GFR by bardoxolone methyl is not likely due to transient hyperfiltration. This impact on renal function (eGFR) could suggest a promising effect of bardoxolone methyl on long-term renal structural change (chronic action), as shown in several animal studies (Aminzadeh et al. 2014; Tan et al. 2014; Son et al. 2015) . Studies using streptozotocin-induced diabetic model animal also suggested the different effect of amlodipine and bardoxolone methyl on the kidney, that is, an analog of bardoxolone methyl attenuated the renal pathology (glomerularsclerosis and tubulointerstitial injury) (Tan et al. 2014 ) while amlodipine did not (Flynn et al. 2012) . Results of upcoming longterm observations are expected to shed more light on these mechanisms.
Clinical trials of the Nrf2 activators in non-kidney diseases
Challenges in clinical applications of Nrf2 activators were summarized in Table 2 , including non-kidney diseases. Currently, Tecfidera® (dimethyl fumarate) is on the market for treatment of multiple sclerosis with a putative mechanism of action that activates the Nrf2 K. Yamawaki et al. Toxicology and Applied Pharmacology 360 (2018) 30-37 pathway, and a phase 3 trial of monomethyl fumarate prodrug, diroximel fumarate, is being conducted for the same target disease. Bardoxolone methyl is also currently in phase 3 trial for connective tissue disease-associated pulmonary arterial hypertension in addition to kidney disease. In parallel with the development with bardoxolone methyl, specific modification at C-17 of CDDO was used to synthesize omaveloxolone. Omaveloxolone is currently under clinical investigation for Friedreich's ataxia, and no safety issues have been raised so far. Nrf2 activators are also being evaluated in ongoing trials for other diseases including amyotrophic lateral sclerosis (ALS) and subarachnoid hemorrhage, underscoring their high potential as therapeutic agents.
Conclusions and future perspectives
The development of drugs for kidney diseases has been plagued by the high degree of difficulty in conducting clinical trials and the complex nature of the disease progression. However, as described in this review, recent developments, including the improved endpoint for clinical trials and progress in clinical trials of drugs with anti-oxidative effects mediated via the Keap1-Nrf2 system (such as bardoxolone methyl) have changed this view, generating great expectations for the future of drug development for kidney diseases. Efforts are ongoing to develop a drug that would significantly reduce the disease burden for both patients and their families. Oxidative stress and inflammation caused by multiple stimuli such as diabetes and hypertension provoke two possible actions for kidney: 1) dynamic action and 2) chronic action, which both lead to GFR decline. Dynamic action includes the ROS-induced mesangial cell contraction (Ding et al. 2013 ) and glomerular endothelial dysfunction due to decreased NO bioavailability (Heiss et al. 2009; Aminzadeh et al. 2013) , which causes the reduction of filtration coefficient (K f ). Chronic action, due to the increase of inflammatory cytokines and extracellular matrix deposition, causes the kidney structural changes such as tubulointerstitial fibrosis and mesangial expansion (Aminzadeh et al. 2014; Tan et al. 2014; Son et al. 2015) . Bardoxolone methyl suppresses the oxidative stress and inflammation, the upper stream of this scheme, resulting the improvement of kidney function (GFR).
